The Termeer Foundation的动态

I enjoyed hearing Simon Beaulah present on the interesting work and mission of PrecisionLife at the CIC (Cambridge Innovation Center) Venture Café yesterday evening. It’s exciting to see progress in the identification of subpopulations of patients living with chronic diseases, and consider the impact this information could have on: - The identification of novel drug targets - The design of clinical trials - How diagnostic tools are linked with treatment approvals - How the industry may need to adapt as precision medicine makes once ‘common’ diseases rare via the subcategorisation of patient groups

MARAbio, led by CEO Michael Paul, has just secured a $19 million funding round to develop a groundbreaking antibody blood test for autoimmune-related autism. This innovative approach could open up new frontiers in early detection and personalised treatment in the realm of autoimmune disorders. What does this mean for the biotech and diagnostics industry? ?? A potential game-changer in diagnostics: By leveraging antibody detection, this test could significantly improve early diagnosis and intervention strategies for autism linked to autoimmune responses. ?? Innovative science at its best: The research underpinning this development not only deepens our understanding of autism but also highlights the critical role of immune system responses in neurological conditions. ?? The impact of $19 million in funding: This substantial investment will accelerate MARAbio’s R&D efforts, bringing us closer to more targeted diagnostic tools for individuals affected by complex medical conditions. This news raises key questions: Could antibody-based diagnostics become the new standard for early detection in neurological conditions? How will these advancements reshape our approach to personalised medicine? The intersection of immunology and neurology continues to be a hotbed of innovation, and MARAbio's progress is a testament to the power of scientific collaboration and investment in transforming patient outcomes. #Biotech #MedicalDiagnostics #AutoimmuneDisease #AutismResearch #Innovation #Healthcare #EarlyDetection #PersonalisedMedicine #MedicalAdvancements #BiotechCommunity #LifeSciences #ScientificInnovation

Is your Parkinson's drug the key to a better tomorrow? Evaluate efficacy faster with Clario. Parkinson's disease is the fastest-growing neurological condition globally, with the prevalence expected to double by 2040. More research is needed to better understand the disease pathology and identify more effective treatments. Clario has supported over 350 Parkinson’s disease trials for biotech, pharma, and CROs of all sizes across the globe. We approach each project with: ? Specialized neuroscience expertise ? Dedicated project management ? Flexible collaboration ?? Partner with Clario to evaluate your compound’s effectiveness faster. ??Learn more about our neuroscience solutions. https://lnkd.in/d9tCjbSt #ClarioNeuroscience #ParkinsonsResearch #ClinicalTrials

Are you attending #BIO2024? Don’t miss our panel on the most pressing unmet need in medicine: brain disorders. Hear from Basking CEO Rich Shea and other #neurology and #biotech leaders about how innovative technologies to uncover the function and dysfunction of the brain at the molecular and cellular level are transforming #neurotherapeutics. ?? Targeting the Brain: How Biotech is Uncovering the Biology of Brain Disease for Precision Neurotherapeutics ??? Tuesday June 4 ? 11 am - 12 pm PT ?? 26A ??Alaa Halawa, MBA, Executive Director and Head of Healthcare, US Ventures, Mubadala Capital ??Carol Suh, MBA, Co-founder & Chief Operating Officer, Neumora ??Joanne Taylor, PhD, Senior Vice President, Research, Gain Therapeutics ??Rich Shea, MBA, CEO, Basking Biosciences ??Craig Thompson, CEO, Cerevance https://lnkd.in/eUz8vPrg #pharma #drugdiscovery #drugdelivery #innovation #stroke #drugdevelopment #clinicalresearch #clinicaltrials #neurology

Dr. Ronald Klatz, MD, DO Worldhealth.net Researchers have developed a blood test to detect Parkinson's disease early by analyzing extracellular vesicles (EVs). By isolating EVs and examining their content, they identified the protein phospharylated α-synuclein, which is present in Parkinson's patients. This ultra-sensitive assay can detect #disease markers within EVs before clinical symptoms appear, enabling earlier #diagnosis. #worldhealth #neuroscience #regenerativemedicine #medicine #parkinsons #clinicalresearch #health https://lnkd.in/gRmHwezh

The importance of testing #blood for #biomarkers is brilliantly highlighted here in this article

Alongside the many breakthroughs in the #Alzheimers #DrugDevelopment space, the diagnostics landscape is rapidly evolving, too. Researchers are exploring ways to improve the accessibility and scalability of #amyloid blood tests, and working to validate the complementary #biomarkers that will support drug development. Our Co-Founder and Chief Science Officer, Howard Fillit, MD, connected with Rowan Walrath of C&EN to discuss the ADDF's Diagnostics Accelerator (DxA) and its funding of blood-based biomarkers and #digital diagnostic tools, offering his prediction that #BloodTests will eventually replace the current gold standard PET scans and spinal taps for Alzheimer's #diagnosis. Throughout the article, diagnostic and biomarker research by ADDF- and DxA-funded investigators and biotechs like C2N Diagnostics, ALZpath Inc., Quanterix, RetiSpec, Rhoda Au, and DiaMiR Bio are mentioned. Read the full article here: https://bit.ly/3JaGZXR

?? The future of #neurotherapeutics is now! Attend this #BIO2024 panel to hear from top leaders in the field as they discuss groundbreaking tools and strategies for treating brain disorders.

Please join us for the inaugural ADDF Summit: Advancements in Novel Therapeutics and Combination Therapy on Monday, October 28th, preceding #CTAD24. The Summit is an invite-only, full-day meeting that brings together expert collaboration of #scientists from academia and biotech, #industry and #government, and other thought leaders. The symposium will explore cutting-edge science that will accelerate the development of new treatments—guided by the #BiologyOfAging—and advance the field of Alzheimer's disease with innovative approaches around #CombinationTherapy and #PrecisionMedicine. This year’s agenda includes an array of ADDF leadership including CEO Mark Roithmayr, and Co-Founder and Chief Science Officer, Howard Fillit, MD, as well as leading ADDF-funded researchers like Miia Kivipelto, MD, PhD, Jeffrey Cummings, MD, ScD, Henrik Zetterberg, MD, PhD, Miranda Orr, PhD, and more. Funded institutions set to present include C2N Diagnostics, GliaPharm SA, Coya Therapeutics, Inc., Cognito Therapeutics, Inc., and Alzheimer's Research UK. Visit the website to learn more: https://lnkd.in/eSu8EWqr

Today, we are to spotlight session 1 of our Rare Disease Awareness Workshop Webinar, featuring three remarkable patient advocacies. Join us as we dive deeper into the inspiring stories of these groundbreaking pioneer foundation founders, who are also patient parents. Discover the valuable insights from Julia Vitarello, ?Michaelle Jinnette, MA, LMFT,?and Amber N. Freed During this session, participants will gain profound insights into:?? ?Learning from real-life cases on effective collaboration with academia and industry as a patient advocate for drug development, while navigating the pathway towards a cure.? ?Understanding the significant challenges patients are facing in realizing personalized medicine; ?? Watch now: https://lnkd.in/d6pWFjnT Let’s share these impactful discussions widely, fostering greater awareness and engagement within the rare disease community.??? #RareDisease?#Innovation?#Webinar?#Healthcare?#Leadership?#iXCells?#DrugDevelopment?#PersonalizedMedicine?#StemCellsResearch?#RegenerativeMedicine?#Biotech?#RareDiseaseAwareness?#ASODevelopment?#Neuroscience?#CNSDiseases?#PatientFocusedTherapy?